NCT06306118 Autoguide Positioning Device for Multiple Stereotactic Biopsies
| NCT ID | NCT06306118 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Graz |
| Condition | Multiple Stereotactic Tumor Biopsies During a Brain Tumor Resection |
| Study Type | OBSERVATIONAL |
| Enrollment | 25 participants |
| Start Date | 2024-04-15 |
| Primary Completion | 2025-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25 participants in total. It began in 2024-04-15 with a primary completion date of 2025-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this clinical study should be that, in the context of planned resections of glial brain tumors, pieces of tissue (biopsies) are removed from the tumor at several specific locations before the actual tumor resection takes place. The aim of these biopsies in advance to the actual tumor resection will be to receive tumor tissue samples not altered in such a way that it is no longer adequate for further treatment. If not adequate, a so-called "undergrading" could occur, which means that the biological structure of the tumor is misjudged and further therapy does not achieve the desired effect in the patient. On the one hand, certain tumor regions can drift due to a "brain shift" which leads to inaccurate tissue removal, and on the other hand samples are not altered by pressure or bleeding. To carry out these biopsies, a robot positioning device (AutoGuide®) will be used that has already been approved and tested for this type of intervention. The use of the AutoGuide® is intended to ensure that the tumor sample is taken with the greatest possible precision.
Eligibility Criteria
Inclusion Criteria: * Age 18-80 years * Diagnosis of a cerebral lesion with the indication for surgical resection * Written informed consent to participate in the present study * MRI and CT scanner compatibility Exclusion Criteria: * Pregnancy, breast feeding * Patients not able to reason * Age \<18 or \>80 years * Claustrophobia
Contact & Investigator
Stefan Wolfsberger, Prof.
PRINCIPAL INVESTIGATOR
Medical University of Graz
Frequently Asked Questions
Who can join the NCT06306118 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Multiple Stereotactic Tumor Biopsies During a Brain Tumor Resection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06306118 currently recruiting?
Yes, NCT06306118 is actively recruiting participants. Contact the research team at alexander.micko@medunigraz.at for enrollment information.
Where is the NCT06306118 trial being conducted?
This trial is being conducted at Graz, Austria.
Who is sponsoring the NCT06306118 clinical trial?
NCT06306118 is sponsored by Medical University of Graz. The principal investigator is Stefan Wolfsberger, Prof. at Medical University of Graz. The trial plans to enroll 25 participants.